Revolution Medicines Inc.
Revolution Medicines Receives FDA Voucher for Daraxonrasib
Summary
On October 16, 2025, Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the Company a non-transferrable voucher for daraxonrasib, the Company's RAS(ON) multi-selective inhibitor, under the Commissioner's National Priority Voucher pilot program. This voucher can be used to expedite the review of future drug applications, potentially reducing the time required for regulatory approval of new drugs.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement